Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients

Clinical Microbiology and Infection

Volumn 8, Issue 1, 2002, Pages 14-25

  Glauser, M P ^a   Brennscheidt, U ^b   Cornely, O ^c   Grigg, A ^d   Figuera, A ^e   Keyserling, C ^f   Trostmann, U ^f,g   Welling, L ^f   Tack, K ^f  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f PFIZER INC   (United States)

^g Parke Davis GmbH   (Germany)

Author keywords

Amikacin; Cancer patients; Ceftazidimine; Clinafloxacin; Febrile neutropenia; Monotherapy

Indexed keywords

AMIKACIN; ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT; ANTIVIRUS AGENT; CEFTAZIDIME; CLINAFLOXACIN; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL INFECTION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEBRILE NEUTROPENIA; HUMAN; INFECTION PREVENTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL RATE;

BACTERIA (MICROORGANISMS);

EID: 0036038509     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1198-743x.2001.00338.x     Document Type: Article

References (19)

1. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
2. Evolution of antibiotic therapy for infection in neutropenic patients: Studies at MD Anderson Hospital
3. New and unusual infections in neutropenic patients
4. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials
5. Changing epidemiology of infection in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria
6. Initial clinical experience with clinafloxacin in the treatment of serious infections
7. Clinafloxacin in the treatment of hospitalized patients with serious infections: Current status
8. Comparative activities of clinafloxacin against gram-positive and -negative bacteria
9. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin
10. The in vitro activity of CI-960 (clinafloxacin) and CI-990 against routine and multiresistant clinical isolates
11. Categorical data analysis
12. Survivorship analysis for clinical studies
13. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients
14. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
15. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
16. Randomized trial on clinafloxacin monotherapy vs. ceftazidime + amikacin in patients with febrile neutropenia-preliminary data
17. Clinafloxacin (CFL) versus ceftazidime/amikacin (TAZ/AMI) for the treatment of febrile neutropenia: A prospective, randomized study